Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 443

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 443
---
 be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. 

We determined that there are no critical audit matters.

/s/ RBSM LLP

We have served as the Company’s auditor since 2015.

RBSM LLP

7915 FM 1960 West, Ste. 220

Houston, Texas 77070

 F-1 

ENDRA Life Sciences Inc.

Consolidated Balance Sheets

  December 31,  December 31, Assets 2024  2023 Current Assets      Cash $3,229,480  $2,833,907 Prepaid expenses  204,185   198,905 Total Current Assets  3,433,665   3,032,812 Non-Current Assets        Inventory  -   2,622,865 Fixed assets, net  69,281   111,782 Right of use assets  578,013   354,091 Prepaid expenses, long term  365,417   626,610 Other assets  5,986   5,986 Total Assets $4,452,362  $6,754,146          Liabilities and Stockholders’ Equity        Current Liabilities        Accounts payable and accrued liabilities $508,293  $700,754 Lease liabilities, current portion  96,937   173,857 Loans  -   28,484 Total Current Liabilities  605,230   903,095          Long Term Debt        Loans, long term  -   - Lease liabilities  487,482   192,062 Warrant Liability  799,284   - Total Long Term Debt  1,286,766   192,062          Total Liabilities  1,891,996   1,095,157          Stockholders’ Equity        Series A Convertible Preferred Stock, $0.0001 par value; 10,000 shares authorized; 17.488 and 141.397 shares issued and outstanding, respectively  -   1 Series B Convertible Preferred Stock, $0.0001 par value; 1,